Study Finds Link Between Diabetes and Alzheimer's Disease

Published Online: Thursday, August 16, 2012
Many studies have linked diabetes with the onset of Alzheimer’s disease (AD), and now a team of investigators appears to have found direct experimental evidence connecting the conditions.

“Our study identifies emergence of AD pathology in brain and retina as a major consequence of diabetes, implicating dysfunctional insulin signaling in late-onset AD, and a potential relationship between amyloid beta-derived neurotoxins and retinal degeneration in aging and diabetes, as well as AD,” the authors wrote in a study published online on July 11, 2012, in the Journal of Alzheimer’s Disease.

The researchers sought to determine how diabetes instigates late-onset AD. They examined diabetic rabbits displaying AD-type pathology for 15 weeks. After this time, investigators observed a diabetes-induced buildup of amyloid beta oligomers in the brains and retinas of the animals. Oligomers are the neurotoxins thought to cause memory loss in AD.

Another study, published in the April 2, 2012, edition of Journal of Clinical Investigation, found that the characteristics of type 2 diabetes, including abnormal glucose use, metabolic dysregulation, and insulin resistance or deficiency, are seen in the early stage of AD independent of type 2 diabetes.

The new study’s findings may have important implications for future investigation of AD pathogenesis, diagnostics, and therapeutics.

To read more articles in this watch, click:
Psoriasis Associated With Increased Risk of Diabetes Mellitus
Diabetes Drug Shown to Prompt New Cell Growth


Latest Articles
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about some safeguards pharmacists can implement.
A pharmacy robber not only left his fingerprints behind at a pharmacy—he also dropped his wallet containing his identification as he made his escape.
Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).
Treating chronic pulmonary obstructive disease with both inhaled corticosteroids and long-acting bronchodilators remains controversial, but new evidence suggests that this controller combination could reduce mortality risk.
Latest Issues